Benefits and risks of interferon therapy for hepatitis B. (Q37462578)

20 August 2017

title

Benefits and risks of interferon therapy for hepatitis B. (English)

1 reference

20 August 2017

Robert Perrillo

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

issue

5 Suppl

1 reference

20 August 2017

page(s)

S103-11

1 reference

Immune responses in hepatitis B virus infection

20 August 2017

cites work

1 reference

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

7 January 2021

Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and Is independent of MxA.

1 reference

7 January 2021

Immune effects of alpha-interferon in chronic liver disease

1 reference

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy

1 reference

7 January 2021

Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?

1 reference

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

1 reference

7 January 2021

Pilot study of recombinant human alpha-interferon for chronic type B hepatitis

1 reference

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

7 January 2021

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

1 reference

7 January 2021

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

7 January 2021

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

7 January 2021

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

7 January 2021

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

1 reference

7 January 2021

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

1 reference

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

7 January 2021

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

1 reference

7 January 2021

Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B

1 reference

7 January 2021

Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients

1 reference

7 January 2021

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

1 reference

7 January 2021

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype

1 reference

7 January 2021

Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance

1 reference

7 January 2021

Selection of hepatitis B virus variants with aminoacid substitutions inside the core antigen during interferon-alpha therapy

1 reference

7 January 2021

A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment

1 reference

7 January 2021

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

7 January 2021

1 reference

7 January 2021

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis

1 reference

7 January 2021

Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a

1 reference

7 January 2021

Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy.

1 reference

7 January 2021

Therapy of hepatitis B -- viral suppression or eradication?

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22956

1 reference

20 August 2017

1 reference